Wall Street brokerages predict that United Therapeutics Co. (NASDAQ:UTHR) will announce sales of $345.48 million for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for United Therapeutics’ earnings, with estimates ranging from $316.34 million to $391.62 million. United Therapeutics reported sales of $381.40 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 9.4%. The business is expected to report its next quarterly earnings results on Wednesday, February 26th.
According to Zacks, analysts expect that United Therapeutics will report full year sales of $1.49 billion for the current fiscal year, with estimates ranging from $1.46 billion to $1.53 billion. For the next fiscal year, analysts expect that the company will post sales of $1.34 billion, with estimates ranging from $1.15 billion to $1.55 billion. Zacks’ sales averages are an average based on a survey of research firms that cover United Therapeutics.
UTHR has been the topic of several recent analyst reports. HC Wainwright reissued a “hold” rating and issued a $85.00 target price on shares of United Therapeutics in a report on Friday, November 1st. ValuEngine lowered shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 4th. Bank of America initiated coverage on shares of United Therapeutics in a report on Tuesday, December 3rd. They issued an “underperform” rating and a $80.00 target price on the stock. JPMorgan Chase & Co. raised shares of United Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $116.00 to $120.00 in a report on Friday, January 31st. Finally, BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. United Therapeutics presently has a consensus rating of “Hold” and an average target price of $116.17.
UTHR stock traded up $0.20 during mid-day trading on Tuesday, hitting $104.19. The stock had a trading volume of 233,583 shares, compared to its average volume of 453,274. The company has a current ratio of 4.11, a quick ratio of 3.91 and a debt-to-equity ratio of 0.28. United Therapeutics has a 52 week low of $74.31 and a 52 week high of $128.94. The firm has a market capitalization of $4.56 billion, a P/E ratio of -48.01, a P/E/G ratio of -1.57 and a beta of 1.01. The firm has a fifty day simple moving average of $92.51 and a 200 day simple moving average of $87.07.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Great Point Partners LLC purchased a new stake in United Therapeutics in the third quarter worth $37,483,000. Renaissance Technologies LLC increased its holdings in shares of United Therapeutics by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 3,544,433 shares of the biotechnology company’s stock valued at $312,194,000 after purchasing an additional 332,155 shares during the period. AJO LP acquired a new position in shares of United Therapeutics in the fourth quarter valued at about $20,146,000. FMR LLC increased its holdings in shares of United Therapeutics by 9.2% in the fourth quarter. FMR LLC now owns 2,383,549 shares of the biotechnology company’s stock valued at $209,943,000 after purchasing an additional 201,569 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of United Therapeutics by 39.4% in the third quarter. Point72 Asset Management L.P. now owns 640,243 shares of the biotechnology company’s stock valued at $51,059,000 after purchasing an additional 180,803 shares during the period. Institutional investors own 93.26% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: What sectors are represented in the FTSE 100 index?
Get a free copy of the Zacks research report on United Therapeutics (UTHR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.